New drug LEO 153339 tested for safety in healthy people
NCT ID NCT04883333
First seen May 01, 2026 · Last updated Jun 24, 2026 · Updated 9 times
Summary
This early-stage trial tested the safety and tolerability of a new drug called LEO 153339 in 108 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The study focused on how the body absorbs and processes the drug, and whether it causes any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma Investigational Site
Groningen, NZ, 9728, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LEO 153339
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.